Bharat Heavy Electricals Limited (BHEL) announced that the state-owned company has successfully commissioned five pumping units of the 7x139 MW Kaleshwaram Lift Irrigation Scheme (LIS) Package 8, in Telangana.

Market watchdog Securities and Exchange Board of India (SEBI) has imposed a total penalty of over Rs. 22 crore on Aurobindo Pharma, its promoter PV Ramprasad Reddy, his wife P Suneela Rani and also other related entities for violating insider trading norms.

Trent Limited on Tuesday informed that the company has agreed to acquire 51 per cent of the share capital of Booker India Private Limited (BIPL) for a consideration of Rs. 22 crore approximately.

Dish TV India is planning to launch android set top boxes. As a result, the shares rallied around 10 per cent intraday on Tuesday.

RPP Infra Projects, on Tuesday, informed the bourses that the company along with its JV partner, has secured a new order worth Rs. 414 crore.

Preparing a budget is the beginning of your financial wellbeing. It helps you to closely monitor your earnings and expenses. If you have made a well thought budget it will help you to achieve your financial goals.

The stocks to watch out on September 25 include Pennar Industries, Adani Enterprises, RPP Infra, InfoBeam Technologies and Centum Electronics.

Consumer face segment would benefit the most, given higher effective tax rates of over 30 per cent, while export-linked sectors such as IT and pharma will benefit the least, accounting for only 5-6 per cent of potential savings. That’s because they already enjoy low effective tax rates. 

Pennar Industries has informed the bourses on Tuesday that it has doubled its Cold Drawn Welded (CDW) tubes manufacturing capacity. Pennar is one of the leading suppliers of CDW tubes to India’s automotive and construction equipment sectors.

Shares of Suven Life Sciences jumped more than 4 per cent after the company announced dose administration of the first patient in a Phase 2A clinical trial of SUVN G-3031, a Histamine H3 receptor inverse agonist in a double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 2 mg and 4 mg SUVN-G3031 compared to placebo in patients with narcolepsy with or without cataplexy.